Compare Figs Inc (FIGS) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Merck & Co., Inc. — how do they compare? Figs Inc trades at $14.37 (market cap $2.37B), while Merck & Co., Inc. trades at $132.79 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 135.8× Figs Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Figs Inc pays none. Which is the better fit depends on your goals.
| FIGS | MRK | |
|---|---|---|
Market Cap | $2.37B | $321.77B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $131.84 |
52-Week Low | $6.57 | $77.60 |
Enterprise Value | $2.13B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $14.41, up 0.14% with strong technical momentum as moving averages signal bullish sentiment. The company reported impressive Q2 2026 results with 29% revenue growth and raised full-year guidance, while maintaining robust gross margins of 68.9%. Recent institutional buying and positive analyst coverage support the stock's upward trajectory despite rich valuation multiples.
Outlook remains positive with accelerating revenue growth and margin expansion, though the premium valuation (P/E 43.2) creates high expectations. Key risks include execution challenges in the second half and competitive pressures in healthcare apparel. The consensus price target of $19.50 suggests 35% upside potential from current levels.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
